State-of-the-art management of nasopharyngeal carcinoma: Current and future directions

British Journal of Cancer

Volumn 92, Issue 5, 2005, Pages 799-806

  Agulnik, M ^a   Siu, L L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; Immunotherapy; Molecular targeted agents; Nasopharyngeal carcinoma; Radiotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; TEGAFUR; URACIL; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; SHORT SURVEY; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; NASOPHARYNGEAL NEOPLASMS;

EID: 16244376430     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602449     Document Type: Short Survey

References (41)

1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF (1998) Chemoradiotherapy vs radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16: 1310-1317
2. Al-Sarraf M, LeBlanc M, Giri PGS, Fu K, Cooper J, Vuong T, Forastiere A, Adams G, Sakr W, Schuller D, Ensley J (2001) Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients (pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: final report. Proc Am Soc Clin Oncol 20: 227a (abstract 905)
3. Bar-Sela G, Kuten A, Ben-Eliezer S, Gov-Ari E, Ben-Izhak O (2003) Expression of HER2 and C-KIT in nasopharyngeal carcinoma: implications for a new therapeutic approach. Mod Pathol 16: 1035-1040
4. Bonner JA, Giralt J, Harari PM, Cohen R, Jones C, Sur RK, Rabin D, Azarnia N, Needle MN, Ang KK (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 22: 489a (abstract 5507)
5. Chan AT, Ngan R, Teo P, Leung SF, Yiu HY, Yeo W, Mok T, Cheung FY, Kwan W, Zee B (2004) Final results of a phase III randomized study of concurrent weekly cisplatin-RT vs RT alone in locoregionally advanced nasopharyngeal carcinoma (NPC). J Clin Oncol 22: 493a (abstract 5523)
6. Chan AT, Teo PM, Leung TW, Leung SF, Lee WY, Yeo W, Choi PH, Johnson PJ (1995) A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33: 569-577
7. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ (2002) Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20: 2038-2044
8. Chan ATC, Hsu MM, Goh BC, Hui EP, Liu TW, Millward M, Chang AY, Ma BB, Hong RL, Lin X (2003) A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy. Proc Am Soc Clin Oncol 22: 497 (abstract 2000)
9. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY (2002) A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 52: 1238-1244
10. Chua DT, Nicholls JM, Sham JS, Au GK (2004) Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59: 11-20
11. Chua DT, Sham JS, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, Vootiprux V, Cheirsilpa A, Azhar T, Reksodiputro AH (1998) Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy vs radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 83: 2270-2283
12. Chua DTT, Ma J, Sham JST (2004) Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 22: 494s (abstract 5524)
13. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E (1994) Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 21: 382-397
14. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand JP, Simon J, Cvitkovic E (2000) Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol 18: 1324-1330
15. Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: 1604-1608
16. Guang-Wu H, Sunagawa M, Jie-En L, Shimada S, Gang Z, Tokeshi Y, Kosugi T (2000) The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope 110: 2066-2069
17. Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T (2002) A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 94: 2217-2223
18. Hoffman H, Cooper JS, Weber R, Ang K, Porter K, Langer CJ (2004) Changing patterns of practice in the management of nasopharynx carcinoma (NPC): analysis of the National Cancer Database (NCDB). J Clin Oncol 22: 488s (abstract 5501)
19. Hunt MA, Zelefsky MJ, Wolden S, Chui CS, LoSasso T, Rosenzweig K, Chong L, Spirou SV, Fromme L, Lumley M, Amols HA, Ling CC, Leibel SA (2001) Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 49: 623-632
20. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, Leung SF, Zee B, Chan AT (2004) Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 60: 1440-1450
21. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, Wu PM, Law MW, Kwok CC, Yau CC, Wan KY, Chan RT, Choy DD (2004) Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 22: 2643-2653
22. Le QT, Tate D, Koong A, Gibbs IC, Chang SD, Adler JR, Pinto HA, Terris DJ, Fee WE, Goffinet DR (2003) Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 56: 1046-1054
23. Lee AW, Lau WH, Tung SY, Chua D, Chappell R, Siu L, Chia S, Lau J, Law SCK (2004) Prospective randomized study on therapeutic gain achieved by addition of chemotherapy for T1-4N2-3M0 nasopharyngeal carcinoma (NPC). J Clin Oncol 22: 489s (abstract 5506)
24. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53: 12-22
25. Leong JL, Loh KS, Putti TC, Goh BC, Tan LK (2004) Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 114: 153-157
26. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY (2003) Phase III study of concurrent chemoradiotherapy vs radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21: 631-637
27. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS (2004) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350: 2461-2470
28. Lu JJ, Shakespeare TP, Tan LK, Goh BC, Cooper JS (2004) Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in T1 and T2 nasopharyngeal carcinoma. Head Neck 26: 389-395
29. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ, Chan AT (2003) Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck 25: 864-872
30. Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL (2002) Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 95: 2516-2523
31. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY (2001) Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with loco regionally advanced nasopharyngeal carcinoma. J Clin Oncol 19: 1350-1357
32. Pai PC, Chuang CC, Wei KC, Tsang NM, Tseng CK, Chang CN (2002) Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck 24: 748-753
33. Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, Morandi L, Zucali R, Pilotti S, Grandi C, Ambrosini G, Cellini N, Chiavacci A, Colombo A, Dal Fior S, De Maria D, Felci U, Gabriele P, Laddaga M, Magno L, Marziano C, Olmi P, Prino A, Roncoroni L, Torretta A, Zampi G, Zorat PL, De Palo G (1988) Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 6: 1401-1410
34. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE (2004) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2004 Nov 12 [Epub ahead of print].
35. Sultanem K, Shu HK, Xia P, Akazawa C, Quivey JM, Verhey LJ, Fu KK (2000) Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California - San Francisco experience. Int J Radiat Oncol Biol Phys 48: 711-722
36. Talmi YP, Horowitz Z, Bedrin L, Wolf M, Chaushu G, Kronenberg J, Pfeffer MR (2002) Quality of life of nasopharyngeal carcinoma patients. Cancer 94: 1012-1017
37. VUMCA (1996) Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (> or =N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 35: 463-469
38. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Lee KM, Yang E, Machin D (2004) Phase III randomized trial of radiotherapy vs concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety. J Clin Oncol 22: 488s (abstract 5000)
39. Wolden S, Pfister D, Zelefsky M, Rosenzweig K, Chong L, Kraus D, Shah J, Leibel S (2002) Intensity modulated radiation therapy improves locoregional control for nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 21: 240a (abstract 956)
40. Xia P, Fu KK, Wong GW, Akazawa C, Verhey LJ (2000) Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 48: 329-337
41. Yan J, Fang Y, Huang BJ, Liang QW, Wu QL, Zeng YX (2002) Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. Cancer Genet Cytogenet 132: 116-119